Kindred Biosciences Inc Sets New 1-Year High at $17.50 (KIN)
Kindred Biosciences (NYSE:KIN) set a new 52-week high on Friday, American Banking News.com reports. The company traded as high as $17.50 and last traded at $17.26, with a volume of 89,290 shares. The stock had previously closed at $16.48.
A number of research firms have recently commented on KIN. Analysts at Roth Capital initiated coverage on shares of Kindred Biosciences in a research note to investors on Tuesday. They set a “buy” rating and a $20.00 price target on the stock. Separately, analysts at BMO Capital Markets downgraded shares of Kindred Biosciences from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, January 22nd. Finally, analysts at Guggenheim initiated coverage on shares of Kindred Biosciences in a research note to investors on Monday, January 6th. They set a “buy” rating on the stock.
Kindred Biosciences has a 52 week low of $8.75 and a 52 week high of $17.27. The stock has a 50-day moving average of $13.73 and a 200-day moving average of $13.51. The company’s market cap is $259.7 million.
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.